<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04969250</url>
  </required_header>
  <id_info>
    <org_study_id>016 / VATICO</org_study_id>
    <nct_id>NCT04969250</nct_id>
  </id_info>
  <brief_title>Vaccination for Recovered Inpatients With COVID-19 (VATICO)</brief_title>
  <official_title>SARS-CoV-2 Vaccination Strategies in Previously Hospitalized and Recovered COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kirby Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington D.C. Veterans Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>US Department of Veterans Affairs</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prevention and Early Treatment of Acute Lung Injury (PETAL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiothoracic Surgical Trials Network (CTSN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this Phase 4, open-label trial, participants of the ACTIV-3/TICO clinical trial&#xD;
      (NCT04501978) at selected study sites who receive certain pre-specified, blinded&#xD;
      investigational agents or placebo as part of that trial and who have since achieved sustained&#xD;
      recovery from COVID-19 and meet certain criteria, including not having received a COVID-19&#xD;
      vaccination since enrollment, will be randomized to one of four groups to receive the Moderna&#xD;
      mRNA-1273 or the Pfizer BNT162b2 vaccine (mRNA vaccines). No &quot;dummy/placebo&quot; vaccine will be&#xD;
      used.&#xD;
&#xD;
      Choice of Moderna or Pfizer vaccine is determined based on availability at the site. The&#xD;
      choice is individual, although participants vaccinated twice should receive the same type of&#xD;
      vaccine when receiving two injections. The study's objective is to evaluate if the vaccine is&#xD;
      best administered early or deferred after recovery, and whether one injection provides&#xD;
      comparable immune response to a two injection course of vaccination. Participants will remain&#xD;
      blinded to the interventions received in the ACTIV-3/TICO study, however allocation to the&#xD;
      timing of vaccination and to one or two vaccinations in this (VATICO) study is not blinded.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants from the ACTIV-3/TICO clinical trial must still be blinded and be within 28 to&#xD;
      90 days after their initial TICO randomization. They will be randomized as part of a 2x2&#xD;
      factorial design to one of four groups:&#xD;
&#xD;
      (i) Immediate versus 12 week deferral of first dose administration, and also (ii) One dose&#xD;
      only, versus two doses to be given 4 weeks apart.&#xD;
&#xD;
      The primary objectives of this study are:&#xD;
&#xD;
      (i) To estimate the difference in neutralizing antibody (NAb) response to the mRNA vaccine&#xD;
      from baseline to Week 48 among participants vaccinated early versus deferred, and (ii) To&#xD;
      estimate the difference in NAb response to this vaccine among participants vaccinated once&#xD;
      versus twice.&#xD;
&#xD;
      A key secondary objective is to ascertain the effect, if any, of SARS-CoV-2 monoclonal&#xD;
      antibodies, and other interventions that have been studied in hospitalized COVID-19 subjects,&#xD;
      on natural and vaccine-induced immunity.&#xD;
&#xD;
      Participants will be offered enrollment between 28 and 90 days after receiving select&#xD;
      ACTIV-3/TICO investigational agents or placebo. Participants will have blood collected at&#xD;
      time of enrollment, and at Weeks 12, 24 and 48 after study entry. Approximately 640&#xD;
      participants will be recruited. The total sample size will depend on how many investigational&#xD;
      agents/placebo are evaluated in ACTIV-3/TICO.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 25, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neutralizing antibody (NAb) levels following vaccination</measure>
    <time_frame>Thru Week 48</time_frame>
    <description>Evaluated using the ratio of geometric mean responses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody levels 12 weeks after first vaccination</measure>
    <time_frame>12 weeks after first vaccination</time_frame>
    <description>Evaluated using the ratio of geometric mean responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated percentage of participants with &gt; 16-fold differences in NAbs</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Evaluated using the ratio of geometric mean responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated percentage of participants with &gt; 16-fold differences in NAbs</measure>
    <time_frame>Just before vaccination to 12 weeks post-vaccination</time_frame>
    <description>Evaluated using the ratio of geometric mean responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated percentage of participants with 8-16-fold differences in NAbs</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Evaluated using the ratio of geometric mean responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated percentage of participants with 8-16-fold differences in NAbs</measure>
    <time_frame>Just before vaccination to 12 weeks post-vaccination</time_frame>
    <description>Evaluated using the ratio of geometric mean responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated percentage of participants with 4-8-fold differences in NAbs</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Evaluated using the ratio of geometric mean responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated percentage of participants with 4-8-fold differences in NAbs</measure>
    <time_frame>Just before vaccination to 12 weeks post-vaccination</time_frame>
    <description>Evaluated using the ratio of geometric mean responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated percentage of participants with 2-4-fold differences in NAbs</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Evaluated using the ratio of geometric mean responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated percentage of participants with 2-4-fold differences in NAbs</measure>
    <time_frame>Just before vaccination to 12 weeks post-vaccination</time_frame>
    <description>Evaluated using the ratio of geometric mean responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated percentage of participants with &lt; 2-fold differences in NAbs</measure>
    <time_frame>Baseline and Week 48</time_frame>
    <description>Evaluated using the ratio of geometric mean responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated percentage of participants with &lt; 2-fold differences in NAbs</measure>
    <time_frame>Just before vaccination to 12 weeks post-vaccination</time_frame>
    <description>Evaluated using the ratio of geometric mean responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of post-vaccine level/pre-vaccine level</measure>
    <time_frame>Up to Week 24</time_frame>
    <description>Measured by change in NAb response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite number of death, serious adverse event (SAE), grade 3 AEs and grade 4 AEs</measure>
    <time_frame>12 weeks following first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Deaths</measure>
    <time_frame>Thru Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of SAEs</measure>
    <time_frame>Thru Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants assigned 2nd vaccine dose who do not receive it for any reason</measure>
    <time_frame>Thru Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants assigned 2nd vaccine dose who do not receive it due to an AE following first dose</measure>
    <time_frame>Thru Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-adherence to assigned treatment strategy</measure>
    <time_frame>Thru Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">640</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Group I1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate, one dose. Vaccination at study entry</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group I2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate, two doses. Vaccination at study entry and Week 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deferred, one dose. Vaccination at Week 12 only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deferred, two doses. Vaccination at Week 12 and Week 16</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Moderna mRNA-1273 COVID-19 vaccine</intervention_name>
    <description>100 µg intramuscular injection</description>
    <arm_group_label>Group D1</arm_group_label>
    <arm_group_label>Group D2</arm_group_label>
    <arm_group_label>Group I1</arm_group_label>
    <arm_group_label>Group I2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pfizer BNT162b2 COVID-19 vaccine</intervention_name>
    <description>30 µg intramuscular injection</description>
    <arm_group_label>Group D1</arm_group_label>
    <arm_group_label>Group D2</arm_group_label>
    <arm_group_label>Group I1</arm_group_label>
    <arm_group_label>Group I2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participating in (ACTIV-3) TICO trial and received a selected blinded investigational&#xD;
             agent, or placebo for that agent, at selected sites.&#xD;
&#xD;
          -  Willingness to strictly adhere to the randomly allocated dosage number and schedule&#xD;
             for vaccine administration.&#xD;
&#xD;
          -  Participant is between Day 28 and Day 90 TICO visits inclusive at time of&#xD;
             randomization.&#xD;
&#xD;
          -  At time of screening for this study, has experienced sustained recovery for at least&#xD;
             two consecutive weeks, i.e. having return uninterrupted to the person's premorbid&#xD;
             living facility (or equivalent) for at least 2 consecutive weeks.&#xD;
&#xD;
          -  Ability and willingness of participant (or legally authorized representative) to&#xD;
             provide informed consent prior to initiation of any study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receipt of a SARS-CoV-2 (COVID-19) vaccine after enrollment into TICO. Participants&#xD;
             who received a SARS-CoV-2 vaccine prior to enrollment in TICO may be enrolled in this&#xD;
             study.&#xD;
&#xD;
          -  Known allergy to any component of the study eligible vaccine(s).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Jens Lundgren</last_name>
    <role>Principal Investigator</role>
    <affiliation>INSIGHT Copenhagen International Coordinating Centre, Rigshospitalet, University of Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>If interested in participating in this study, please contact the appropriate site or</last_name>
    <phone>send email to</phone>
    <email>tico@insight-trials.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Do not include personal information in email. Type VATICO in subject line</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center (Site 208-002), 8700 Beverly Blvd</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Stanford University Hospitals &amp; Clinics (Site 203-003), Stanford University, School of Medicine, 300 Pasteur Dr., Grant Bldg, Room S011</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (Site 066-002), 1124 W. Carson St., CDCRC</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Public Health Institute at Denver Health (Site 017-004), 660 Bannock Street</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Washington DC VA Medical Center (Site 009-004), 50 Irving Street, NW.</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20422</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hillsborough County Health Department, University of South Florida (Site 032-001), 1105 E. Kennedy Blvd.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Minneapolis VA Medical Center (Site 105-001), 1 Veterans Drive</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Duke University Hospital (Site 301-006), 2301 Erwin Road</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticoctsn@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Dot not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health (Site 210-001), Medical Center Boulevard</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticopetal@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital (Site 080-036), 593 Eddy St.</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticonih@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital (Site 080-039), 164 Summit Ave.</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticonih@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHRISTUS Spohn Shoreline Hospital (Site 080-001), 600 Elizabeth Street</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticonih@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center (Site 084-001), 1936 Amelia Court, 2nd Floor</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Parkland Health and Hospital Systems (Site 084-002), James Aston Ambulatory Care Center - Clinical Research Unit, 5303 Harry Hines Blvd., Ste U-9.300</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticowdc@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron (Site 626-033), Passeig Vall Hebron, 119-129</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona (Site 626-004), Carrer de Villaroel 170</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol (Site 626-003) Carretera de Canyet, s/n</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova (Site 026-035), Institut de Recerca Biomèdica de Lleida, Av. Rovira Roure, 80</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón (Site 626-001), Servicio de Inmunología Clínica, Departamento de Medicina Interna, Dr. Esquerdo, 46</name>
      <address>
        <city>Madrid</city>
        <zip>28017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticocph@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MRC/UVRI &amp; LSHTM Uganda Research Unit (Site 634-601), Plot 51-59 Nakiwogo Road, P.O. Box 49</name>
      <address>
        <city>Entebbe</city>
        <zip>256</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Gulu Regional Referral Hospital (Site 634-603), P.O. Box 160</name>
      <address>
        <city>Gulu</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital, Nsambya (Site 634-607), Nsambya Road Nsambya Hill, P.O. Box 7146</name>
      <address>
        <city>Kampala</city>
        <zip>256</zip>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Makerere University Lung Institute (634-604), Mulago National Referral Hospital</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Lira Regional Referral Hospital (Site 634-605), Plot 9/19, 21-41 Ngetta Road Police Road</name>
      <address>
        <city>Lira</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Masaka Regional Referral Hospital (Site 634-606), MRC/UVRI and LSHTM Uganda Research Unit, Plot 6 Circle Road, PO Box 556</name>
      <address>
        <city>Masaka</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>If interested in participating at this site, enter site name and VATICO in subject line of email and send to</last_name>
      <email>ticolon@insight-trials.org</email>
    </contact>
    <contact_backup>
      <last_name>Do not include personal information in email</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>Uganda</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>https://www.cdc.gov/coronavirus/2019-nCoV/index.html</url>
    <description>CDC (Centers for Disease Control and Prevention): Coronavirus (COVID-19) website</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/clinical-trials/participant-guide</url>
    <description>A Participant's Guide to Clinical Trials (NIAID)</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/clinical-trials/find-a-clinical-trial</url>
    <description>Find a Clinical Trial</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/clinical-trials</url>
    <description>Clinical Trials at NIAID</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute for Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>https://www.covid19treatmentguidelines.nih.gov/</url>
    <description>NIH COVID-19 treatment guidelines</description>
  </link>
  <link>
    <url>https://www.who.int/emergencies/diseases/novel-coronavirus-2019/</url>
    <description>WHO COVID-19 treatment guidelines</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>COVID 19</keyword>
  <keyword>Coronaviridae Infections</keyword>
  <keyword>Coronavirus Infections</keyword>
  <keyword>RNA Virus Infections</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Nidovirales Infections</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>SARS Coronavirus</keyword>
  <keyword>VATICO</keyword>
  <keyword>ACTIV-3</keyword>
  <keyword>ACTIV3</keyword>
  <keyword>TICO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

